Hazel Hunt
Chief Tech/Sci/R&D Officer bei CORCEPT THERAPEUTICS INCORPORATED
Vermögen: 2 Mio $ am 31.03.2024
Profil
Hazel Hunt is currently the Chief Scientific Officer at Corcept Therapeutics, Inc. She previously worked as the Operations Director at Pulmagen Therapeutics (Synergy) Ltd.
and as the Director-Chemistry & Operations at Argenta Bank en Verzekeringsgroep NV.
Hazel also held positions as a Principal at the University of Oxford and the University of California, Davis, as well as a Senior Chemist at Glaxo Group Research Ltd.
She completed her undergraduate degree at the Australian National University and obtained a doctorate from the University of Southampton.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 09.02.2024 | 93 354 ( 0,09% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Hazel Hunt
| Unternehmen | Position | Beginn |
|---|---|---|
| CORCEPT THERAPEUTICS INCORPORATED | Chief Tech/Sci/R&D Officer | 01.01.2011 |
Ehemalige bekannte Positionen von Hazel Hunt
| Unternehmen | Position | Ende |
|---|---|---|
Pulmagen Therapeutics (Synergy) Ltd.
 Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Chief Operating Officer | 01.01.2011 |
Argenta Bank en Verzekeringsgroep NV
 Argenta Bank en Verzekeringsgroep NV Major BanksFinance Argenta Bank en Verzekeringsgroep NV is a customer-centric bank that prioritizes the needs of its clients. Argenta Bank en Verzekeringsgroep is based in Antwerp, BE, and has subsidiaries in Belgium, Germany, Luxembourg, and the Netherlands. The Belgian company aims to make banking easy for its customers, and this is reflected in its approach to business. The private company was founded in 1956 by Karel van Rompuy, and Peter Devlies has been the CEO of the company since 2023. | Corporate Officer/Principal | 01.01.2011 |
| Glaxo Group Research Ltd. | Corporate Officer/Principal | - |
| University of California, Davis | Corporate Officer/Principal | - |
| University of Oxford | Corporate Officer/Principal | - |
Ausbildung von Hazel Hunt
| Australian National University | Undergraduate Degree |
| The University of Southampton | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CORCEPT THERAPEUTICS INCORPORATED | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Pulmagen Therapeutics (Synergy) Ltd.
Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Commercial Services |
Argenta Bank en Verzekeringsgroep NV
Argenta Bank en Verzekeringsgroep NV Major BanksFinance Argenta Bank en Verzekeringsgroep NV is a customer-centric bank that prioritizes the needs of its clients. Argenta Bank en Verzekeringsgroep is based in Antwerp, BE, and has subsidiaries in Belgium, Germany, Luxembourg, and the Netherlands. The Belgian company aims to make banking easy for its customers, and this is reflected in its approach to business. The private company was founded in 1956 by Karel van Rompuy, and Peter Devlies has been the CEO of the company since 2023. | Finance |
| Glaxo Group Research Ltd. |
